PPARγ expression in breast cancer: Clinical value and correlation with ERβ

Histopathology

Volumn 46, Issue 1, 2005, Pages 37-42

  Papadaki, I ^a   Mylona, E ^a   Giannopoulou, I ^a   Markaki, S ^a   Keramopoulos, A ^a   Nakopoulou, L ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Breast cancer; Ductal breast carcinoma; ER ; Immunohistochemistry; PPAR

Indexed keywords

ESTROGEN RECEPTOR BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CELL INFILTRATION; CONTROLLED STUDY; COOPERATION; CORRELATION ANALYSIS; CYTOPLASM; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIGAND BINDING; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; RELAPSE; STATISTICAL ANALYSIS; SURVIVAL; TRANSCRIPTION REGULATION; BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; FOLLOW UP; GREECE; LUNG CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RECURRENT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR BETA; FEMALE; FOLLOW-UP STUDIES; GREECE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PPAR GAMMA; RECURRENCE;

EID: 13244255740     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2005.02056.x     Document Type: Article

References (30)

1. Kliewer SA, Umesono K, Noonan DJ et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 1992; 1358; 771-774.
2. Gelman L, Fruchart J-C, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Mol. Life Sci. 1999; 55; 832-843.
3. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354; 141-148.
4. Mueller E, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell 1998; 1; 465-470.
5. Elsner E, Muller C, Koshizuka K et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl Acad. Sci. USA 1998; 95; 8806-8811.
6. Weihua Z, Andersson S, Cheng G et al. Update on estrogen signaling. FEBS Lett. 2003; 546; 17-24.
7. Weihua ZH, Andersson S, Cheng G et al. Update on estrogen signaling. FEBS Lett. 2003; 546; 17-24.
8. Järvinen TAH, Pelto-Huikko M, Holli K et al. Estrogen receptor β is coexpressed with ERα and PR and associated with nodal status, grade and proliferation rate in breast cancer. Br. J. Cancer 2002; 86; 250-256.
9. Keller H, Givel F, Perroud M, Wahli W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol. Endocrinol. 1995; 9; 794-804.
10. Houston KD, Copland JA, Broaddus RR et al. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor γ ligands in uterine leiomyoma. Cancer Res. 2003; 63; 1221-1227.
11. Wang X, Kilgore MW. Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma 1 in MDA-MB-231 and MCE-7 breast cancer cells. Mol. Cell. Endocrinol. 2002; 194; 123-133.
12. Bleche I, Parfait B, Laurendeau I et al. Quantification of estrogen receptor α and β expression in sporadic breast cancer. Oncogene 2001; 20; 8109-8115.
13. 2 cell cycle arrest. Cancer Res. 2004; 64; 423-428.
14. Lazennec G, Bresson D, Lucas A et al. ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001; 142; 4120-4130.
15. WHO. Histological typing of breast tumors. In Hartman WH, Uzello L, Sobin LH et al. eds. International histological classification of tumors. Geneva: World Health Organisation. 1981; 15-25.
16. Robbins P, Pinder S, De Klerk N. Histological grading of breast carcinomas: a study of interobserver agreement. Hum. Pathol. 1995; 28; 873-879.
17. Rosen PP, Oberman HA. Tumors of the mammary gland. In Rosai J ed. Atlas of tumor pathology. Washington: Armed Forces Institute of Pathology, 1992; 3-7.
18. Theocharis S, Kanelli H, Politi E et al. Expcession of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer 2002; 36; 249-255.
19. Han SN, Greene ME, Pitts J et al. Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin. Cancer Res. 2001; 7; 98-104.
20. Terashita Y, Sasaki H, Haruki N et al. Decreased proxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn. J. Clin. Oncol. 2002; 32; 238-243.
21. Jiang WG, Redfern A, Bryce RP, Mansel RE. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 2000; 62; 119-127.
22. Jiang WG, Douglas-Jones A, Mansel R. Expression of peroxisome proliferator activated receptor-gamma (PPARγ) and the PPARγ coactivator PGC-1 in human breast cancer correlates with clinical outcomes. Int. J. Cancer 2003; 106; 752-757.
23. Liu H, Zang C, Fenner MH et al. PPARγ ligands and ATRA inhibit invasion of human breast cancer cells in vitro. Breast Cancer Res. Treat. 2003; 79; 63-74.
24. Xin X, Yang S, Korralski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 1999; 274; 9116-9121.
25. Clay CE, Namen AH, Atsumi G et al. Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J. Invest. Mes. 2001; 49; 413-420.
26. Omoto Y, Inoue S, Ogawa S. Clinical value of the wild-type estrogen receptor β expression in breast cancer. Cancer Lett. 2001; 163; 207-212.
27. Nakopoulou L, Lazaris AC, Panayotopoulou EG et al. The favourable prognostic value of oestrogen receptor B immunohistochemical expression in breast cancer. J. Clin. Pathol. 2004; 57; 523-528.
28. Kuiper GG, Lemmen JG, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998; 139; 4252-4263.
29. Tremblay A, Tremblay GB, Labrie F, Gignere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function 1 (AF-1). Mol. Cell 1999; 3; 513-519.
30. Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277; 1508-1510.